Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Patients With Essential Hypertension

NCT00441350 is registered in ClinicalTrials.gov with Menarini Group as lead sponsor.

NCT NCT00441350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00441350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Patients With Essential Hypertension
Lead sponsor
Menarini Group
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2007
Completion date
May 31, 2008
Enrollment
1,004 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension